Diabetes is estimated to be the sixth leading cause of death in the U.S., and is found to occur disproportionately in minority populations. The prevalence of diabetes increased by ~ 50 % from 1990 to 2000, and is still on the rise. The estimated total national cost of diabetes in 2007 was $174 billion, the majority going directly to medical expenditures. In response to this epidemic, there are currently more than 350 candidate drugs in development making diabetes second only to cancer in health-related R&D focus. Considering that adverse cardiovascular events such as heart attack and stroke are the major causes of diabetes related deaths, the FDA recently issued a Guidance for Industry entitled, "Diabetes Mellitus ~ Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes", which recommends that new clinical trials for type 2 antidiabetic therapies demonstrate that the therapy will not result in an unacceptable increase in cardiovascular risk. Currently there are no standard markers for cardiovascular risk in the context of type 2 diabetes. We have created a highly integrated, multidisciplinary research team specifically assembled to discover, validate and translate novel biomarkers for cardiovascular complications of type 2 diabetes for use within drug development. The envisioned biomarkers will better predict the onset of cardiovascular disease in the context of type 2 diabetes and help define the optimal therapeutic or pharmaceutical interventions to significantly improve patient outcomes.
Long standing type 2 diabetes mellitus (T2DM) frequently results in cardiovascular disease (CVD) and associated adverse medical outcomes such as heart attack and stroke. Reports in the past few years have found no or limited correlation between T2DM treatment options and the reduction of CVD comorbidities in diabetic populations. Accordingly, there is an immediate and urgent need for the development of in vivo biomarkers of CVD risk and translation of new findings and technologies into antidiabetic drug development pipelines. Thus, the goal of this project is to establish the pathway for discovery, validation and translation of new biomarkers of cardiovascular risk in diabetes.
|Borges, Chad R; Sherma, Nisha D (2014) Techniques for the analysis of cysteine sulfhydryls and oxidative protein folding. Antioxid Redox Signal 21:511-31|
|Borges, Chad R; Rehder, Douglas S; Jensen, Sally et al. (2014) Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions. Mol Cell Proteomics 13:1890-9|
|Oran, Paul E; Trenchevska, Olgica; Nedelkov, Dobrin et al. (2014) Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay. PLoS One 9:e92801|
|Yassine, Hussein; Borges, Chad R; Schaab, Matthew R et al. (2013) Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl 7:528-40|
|Borges, Chad R; Rehder, Douglas S; Boffetta, Paolo (2013) Multiplexed surrogate analysis of glycotransferase activity in whole biospecimens. Anal Chem 85:2927-36|
|Krastins, Bryan; Prakash, Amol; Sarracino, David A et al. (2013) Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem 46:399-410|